Pixium Vision Archives - Medical Design Sourcing

BCI maker Science acquires retinal implant from Pixium Vision

A rendering of the Prima System’s features, now acquired by Science. [Image from Pixium Vision]Brain-computer interface developer Science Corporation announced today that it acquired the IP and related assets for the Pixium Vision Prima implant.

Neuralink co-founder Max Hodak founded Science, which unveiled its Science Eye brain-computer platform in 2022. The Science Eye is a visual prosthesis. It targets retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD), two forms of serious blindness.

The company now owns the retinal implant technology developed by Pixium Vision as well. France-based Pixium Vision said last fall that it was looking for a potential buyer.

The Prima System, a photovoltaic substitute of photoreceptors, already has FDA breakthrough device designation. It provides simultaneous use of the central prosthetic and peripheral natural vision. The company designed the implant for patients with atrophic dry age-related mac…

MedTech 100 roundup: Industry roars back

In the blink of an eye, the medtech industry exited its spring slump and neared its all-time best performance levels.

MassDevice‘s MedTech 100 Index offered signs of a rebound last week and has built on that momentum, registering a final tally of 109.39 points on April 9. That represents a 2.9% increase from the 106.26-point mark set a week prior (April 2).

The industry’s rebound has been impressive, given that just over one month prior, the index had dropped to 102.16 points (March 8), having just set its all-time best of 110.96 on Feb. 15. Medtech companies had no seen that degree of a fall since October 2020.

Improvements highlight the secure position the industry has nestled into a year on from the height of the COVID-19 pandemic’s impact on medtech, as the industry has produced an 18.5% rise from the pre-pandemic high of 92.32 (set on Feb. 19, 2020), plus a 76.1% increase from the mid-pandemic low of 62.13 (March 23, 2020).

The overall …

Second Sight, Pixium Vision merger plans are over

Second Sight Medical notified Pixium that it decided to unilaterally terminate a memorandum of understanding (MOU) ahead of a planned merger.

In a news release, Pixium said the $27.9 million private placement recently announced and closed by Second Sight was “not only explicitly prohibited under the terms of the [MOU] entered into by the companies on Jan. 5, 2021, but also detrimental to Pixum Vision’s interests.”

Paris-based Pixium said it offered to Second Sight a chance to renegotiate the MOU in order to continue pursuing the business combination while preserving contractual balance and the interests of the company and its shareholders, but the company said Second Sight never responded to the proposals, nor did it demonstrate any willingness to reach such an agreement.

Following the refusal to enter renegotiation discussions, Second Sight notified Pixium on Friday that it decided to terminate the MOU, notwithstanding that the MOU doe…

MedTech 100 roundup: Slight rise for the industry

While medtech’s performance still isn’t mirroring the beginning of 2021, the industry is showing signs of life with a small improvement last week.

The year’s strong start, during which MassDevice‘s MedTech 100 index notched an all-time best of 110.96 points (Feb. 15) came to an end later that month and carried over into March, with the index hitting its lowest recent point on March 8 (102.16), marking a fall at a level not seen since October.

Even after a slight rise earlier this month, the index struggled again two weeks ago with another small dip. However, after coming in at 104.05 on March 19, the index got a slight boost over the past week, finishing at 104.87 on March 26, representing a 0.8% rise.

Despite the up-and-down nature of the past couple of months, the index represents a much better situation for the industry compared to this time a year ago when the COVID-19 pandemic was in full swing. The index is up 13.6% from its pre-p…

DTW Podcast – CEO MacMillan on how COVID-19 strengthened Hologic

Hologic CEO Steve MacMillan says in early March 2020 he didn’t appreciate how COVID-19 would change the world forever. But the diagnostics company quickly rose to the challenge, becoming one of the surer suppliers of diagnostic tests needed to chart the Coronavirus’ severity.

In this DeviceTalks Weekly Podcast, MacMillan shares how Hologic pivoted to meet the calls for help from political leaders in the US and around the world.

He also shares what’s next for the company which has shed its aesthetics business in favor of a tighter new course, a course that includes the creation of an innovative information index that will yield new data on women’s health.

While Hologic rose to the challenge during the pandemic, GuardianLane is ready to help children who are coping with grief, including the loss of loved ones to COVID-19 and other diseases.

CEO Kristina Jones shares the story that won the first pitch contest held by Medtech Color, an organization fo…

Second Sight’s merger with Pixium Vision may fall through

Second Sight‘s plans to raise $27.9 million from a private placement appear to have generated conflict with its would-be owner Pixium Vision.

Pixium informed Second Sight (NSDQ: EYES) yesterday that the private placement would breach the memorandum of understanding the two companies reached in early January, according to a Second Sight filing with the SEC. Second Sight said the dispute could head to court, with Pixium seeking to end the MOU and receive a termination fee of up to $1 million.

Under agreements with accredited investors, Second Sight plans to close the private placement on March 26, selling 4.65 million shares of common stock at $6 apiece. The money will go toward working capital for the artificial vision tech company.

The news comes weeks after Second Sight secured announced FDA approval of its Argus 2s retinal prosthesis system, though questions remained about whether it would ever be manufactured. The planned merger with Prixium wo…

Second Sight gains FDA nod for retinal system that may never be produced

Second Sight Medical (NSDQ: EYES) today announced that the FDA has approved its Argus 2s retinal prosthesis system, but questions remain about whether it will ever be manufactured.

Second Sight announced in March 2020 that it would wind down its operations amid the financial shock of the coronavirus pandemic. In April, the company said it took steps to reduce overhead and conserve liquidity ahead of potential partnering, acquiring, or combining with businesses, just days before pricing a $6.8 million offering of its common stock, which closed in May. An auction of its assets was set for June, and Second Sight announced a merger with Pixium Vision in January.

If the merger closes, Pixium — which makes neuromodulation tech to treat blindness — would become the controlling shareholder, owning 60% of the total equity before a capital raise. The combined company would focus on Pixium’s Prima retinal stimulation system and create a new subsidiary to focus on …